However, upregulation of MCL-1 expression in FBXW7-deficient T-ALL cells increases sensitivity of ABT-737, suggesting that the deletion of FBXW7 causes the drug resistance to Bcl-2 antagonist in T-ALL cell lines through an MCL-1 mediated pathway (62). This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.